How targeted cancer therapies could change the healthcare industry

This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke for an investor and industry update in the personalised medicine and cancer therapy space. 

This week we were joined in office by Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke for an investor and industry update in the personalised medicine and cancer therapy space. 

During the interesting 30 minute session, he discussed the evolution of cancer treatments, what personalised medicines could mean for patients, and PTX’s astounding progress in clinical studies, new CAR-T cell therapy collaborations and future proofing the company.

Avoiding overly complicated jargon, Steven addresses the industry landscape and clinical trials in easy to understand terms, and explains why CAR-T and targeted therapies are hot topics amongst professionals in oncology business development and the biotech industry.

Watch the full Investor Briefing below, including the Q&A session where Steven responds to questions such as, when he expects the personalised cancer medicines to be market ready, and what sets PTX apart from other clinical trial companies.

 

 

Reach Markets have been engaged by PTX to assist with private investor management.

Presented on Tuesday the 26th of November at 12pm (AEDT).

This Week’s News

News

8 May 2024

BHP Xplor winner coming to the ASX

News

16 April 2024

Gold at record highs – so why aren’t gold stocks?

News

22 November 2023

Rare Earths Industry Review: Part 2

General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)

including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.